Which thienopyridine antiplatelet medication and dosing regimen is appropriate for an adult patient?

Thienopyridine Selection and Dosing for Adult Patients

For acute coronary syndrome (ACS) patients undergoing PCI, prasugrel (60 mg loading dose, 10 mg daily maintenance) or ticagrelor (180 mg loading, 90 mg twice daily) are preferred over clopidogrel due to superior efficacy in reducing cardiovascular death, MI, and stent thrombosis. 1

Clinical Decision Algorithm

For ACS with Planned PCI:

First-line options:

• Prasugrel 60 mg loading → 10 mg daily maintenance 1
• Ticagrelor 180 mg loading → 90 mg twice daily 2
• Clopidogrel 300-600 mg loading → 75 mg daily (if prasugrel/ticagrelor contraindicated) 1, 3

Duration: Minimum 12 months for both bare-metal and drug-eluting stents 1

Critical Prasugrel Contraindications:

Absolute:

• Prior stroke or TIA 1, 3, 4
• Active pathological bleeding 1

Relative (generally not recommended unless high-risk features like diabetes/prior MI):

• Age ≥75 years (increased fatal/intracranial bleeding risk) 1, 3, 1
• Body weight <60 kg (consider 5 mg maintenance dose instead of 10 mg) 1, 3, 4

For Post-Fibrinolytic Therapy:

If patient received fibrinolytic without prior thienopyridine:

• Clopidogrel 300 mg loading (age ≤75 years) → 75 mg daily 2, 1
• No loading dose if age >75 years 2

If switching to PCI after fibrinolysis:

• Continue clopidogrel if already started 1
• If no prior thienopyridine: clopidogrel 300-600 mg OR prasugrel 60 mg (once anatomy known) 1

For Medically Managed ACS (No PCI):

• Clopidogrel 300 mg loading → 75 mg daily for minimum 1 month, ideally up to 12 months 3
• Prasugrel is NOT indicated (only approved for PCI in ACS) 1

For Stable CAD/Secondary Prevention:

• Clopidogrel 75 mg daily (no loading dose needed) 5, 6
• Prasugrel not indicated for stable disease 1

Key Pharmacologic Differences

Clopidogrel:

• Delayed onset (several hours to maximal effect) 1, 7
• Variable response due to CYP2C19 polymorphisms 3, 8
• Lower bleeding risk than prasugrel 1, 3
• Wait ≥5 days before CABG 3

Prasugrel:

• Faster onset and more consistent platelet inhibition 1, 3, 9
• Superior reduction in MI and stent thrombosis vs. clopidogrel (HR 0.76 for MI, HR 0.48 for stent thrombosis) 1
• Higher bleeding risk (32% relative increase in major bleeding, 4.19 HR for fatal bleeding) 1
• Wait ≥7 days before CABG 1, 3

Ticagrelor:

• Reversible P2Y12 inhibitor (not a thienopyridine but included for comparison) 2
• Rapid onset, no prodrug activation needed 4
• 90 mg twice daily dosing 2

Special Populations

Elderly (≥75 years):

• Clopidogrel preferred over prasugrel due to bleeding risk 10
• If prasugrel deemed necessary: 5 mg maintenance dose 1, 3

Low body weight (<60 kg):

• Prasugrel 5 mg maintenance (though not prospectively validated) 1, 3, 4
• Consider clopidogrel as safer alternative 11

Obesity (Class ≥2):

• Prasugrel or ticagrelor preferred over clopidogrel (less affected by CYP2C19 polymorphisms) 11
• May require higher clopidogrel doses (doubled) if used 11

Switching Strategies

From ticagrelor to clopidogrel:

• Clopidogrel 600 mg loading → 75 mg daily at time of next scheduled ticagrelor dose 12
• Loading dose provides superior platelet inhibition for first 48 hours 12

From prasugrel to ticagrelor:

• Ticagrelor 90 mg twice daily without loading dose at time of next prasugrel dose 12

From ticagrelor to prasugrel:

• Prasugrel 60 mg loading → 10 mg daily at time of next ticagrelor dose 12

De-escalation rationale:

• Consider after 6-12 months if bleeding risk outweighs thrombotic risk 12, 13
• De-escalation to clopidogrel reduces bleeding without increasing ischemic events in stable patients 13, 10

Common Pitfalls

1. Using prasugrel in patients with prior stroke/TIA - This is contraindicated and increases fatal bleeding risk 1, 3, 4

2. Inadequate clopidogrel loading in urgent PCI - 600 mg loading dose achieves faster platelet inhibition than 300 mg, though 300 mg is FDA-approved 1, 7

3. Continuing prasugrel in elderly without high-risk features - Bleeding risk exceeds benefit in most patients ≥75 years 1, 3

4. Premature discontinuation before 12 months - Dramatically increases stent thrombosis risk, especially with drug-eluting stents 1

5. Not adjusting for body weight with prasugrel - Patients <60 kg have increased bleeding risk on standard 10 mg dose 1, 3